The genetic testing market is expected to grow at a CAGR of 22.7% during the forecast period of 2024 to 2032, driven by advancements in technology, increasing awareness of genetic disorders, and the rising demand for personalized medicine. Genetic testing involves analyzing DNA to identify changes or mutations that may lead to genetic disorders or predispositions to certain health conditions. In 2023, the market generated substantial revenue, largely due to the widespread adoption of next-generation sequencing (NGS) and the growing prevalence of genetic diseases.
The cell lysis and disruption market is expected to grow at a CAGR of 10.3% during the forecast period of 2024 to 2032, driven by increasing demand in biotechnology research, technological advancements, and growing applications in drug discovery and development. Standardization and reproducibility present challenges that need to be addressed for the market to reach its full potential. The segmentation by technique highlights the dominance of reagent-based methods, while physical disruption methods exhibit the highest expected CAGR.
The large molecule bioanalytical technologies market is a dynamic sector vital for advancing research and development in biopharmaceuticals. The large molecule bioanalytical technologies market is expected to grow at a CAGR of 10.6% during the forecast period of 2024 to 2032, driven by technological advancements, rising demand for biologics and cell therapies, and the integration of artificial intelligence. However, challenges in standardization and harmonization pose notable restraints.
The medical biomimetics market is expected to grow at a CAGR of 7% during the forecast period of 2024 to 2032, driven by innovations in cardiovascular, orthopedic, and ophthalmological applications. However, challenges in dental biomimetics adoption present a notable restraint. Market segmentation reflects the diverse applications, with cardiovascular biomimetics leading in revenue in 2023 and orthopedic biomimetics exhibiting the highest anticipated CAGR.
The vitrification market is expected to grow at a CAGR of 17% during the forecast period of 2024 to 2032. The market's growth is fueled by advancements in ART, increasing demand for IVF procedures, and the expanding acceptance of fertility preservation. However, ethical and legal considerations pose significant restraints, requiring the industry to navigate these complexities responsibly. The market's segmentation, based on specimens, end-use, and geographic dynamics, reflects its adaptability to diverse needs and regional variations.
The plasmid DNA manufacturing market is characterized by its critical role in the production of plasmid DNA used in various therapeutic applications. The plasmid DNA manufacturing market is expected to grow at a CAGR of 21% during the forecast period of 2024 to 2032. The ongoing drivers and innovative strategies employed by key players are expected to shape the landscape of plasmid DNA manufacturing, contributing to the development of advanced genetic therapies and personalized medicine solutions.
The animal model market is expected to grow at a CAGR of 8.5% during the forecast period of 2024 to 2032. The identified drivers, including the increasing utilization in cancer research, rising significance in immunological disease studies, and key contributions to infectious disease research, emphasize the pivotal role of animal models in advancing scientific knowledge. The restraint related to ethical and regulatory challenges underscores the industry's responsibility to address ethical considerations and navigate evolving regulatory frameworks.
The cell cryopreservation market plays a vital role in preserving and safeguarding various cell types for applications in research, regenerative medicine, and assisted reproductive technology. The cell cryopreservation market plays a pivotal role in regenerative medicine, assisted reproductive technology, and biobanking. The cell cryopreservation market is expected to grow at a CAGR of 21.5% during the forecast period of 2024 to 2032. While technological challenges exist, the market continues to grow due to the expansion of regenerative medicine, ART, and research activities.
The preparative and process chromatography market is expected to grow at a CAGR of 8.1% during the forecast period of 2024 to 2032. The market has been undergoing significant transformation in recent years, driven by several key factors. The preparative and process chromatography market is poised for robust growth, driven by factors such as pharmaceutical advancements, environmental concerns, and the expansion of biotechnology. As the demand for biopharmaceuticals and high-value chemicals continues to surge, the chromatography market will play a pivotal role in ensuring product quality and purity.
miRNA, or microRNA, are small non-coding RNAs that play a vital role in the regulation of gene expression. The miRNA Sequencing and Assay market revolves around the technologies and methodologies employed to study these RNA molecules, which have been linked to various disease mechanisms and are often the subject of innovative therapeutic research. miRNA sequencing and assay market is estimated to grow at a CAGR of 13.1% from 2024 to 2032, driven by increasing significance in cancer research and technological advancements in RNA sequencing.
The global biotechnology market is anticipated to expand at a CAGR of 15% between 2023 and 2030. Government measures aiming at the modernization of the regulatory environment, improvements in approval processes and reimbursement policies, and standardization of clinical research are driving the market. The expanding influence of personalized medicine and the growing number of orphan drug formulations are creating new opportunities for biotechnology applications, encouraging the emergence of creative biotechnology firms, and enhancing market revenue.
Furthermore, genetically engineered crops and herbicide-tolerant and insect-resistant seeds are gaining popularity and contributing to market expansion. Increasing adoption of tissue culture technology for the production of novel rice variants and disease- and pest-free banana varieties in South Asia and Africa, as well as the use of the technology for the cloning of disease-free and nutrient-rich plant varieties, have propelled agricultural applications for biotechnology. A robust clinical trial pipeline and substantial funding opportunities in tissue engineering and regeneration technologies also drive the industry.
Nanobiotechnology is anticipated to grow at the highest CAGR of 14.8% between 2022 and 2030, due to an increase in nanomedicine approvals and the introduction of advanced technology. For instance, applications of theranostics nanoparticles have gained momentum in order to facilitate quick diagnosis and individualization of therapy choices for several diseases simultaneously. Nanoparticles' low toxicity, smaller size, and chemical adaptability have proven advantageous in overcoming the limitations associated with conventional generic drug administration routes. In addition, tissue engineering and regeneration medicine had a sizable proportion of the market due to government and private expenditures in the field, high healthcare spending, and the existence of numerous mature and emerging competitors in this market.
Acute Market Reports is a market research and strategic consulting company specializing in the biotechnology and healthcare industry. The futuristic research technique offered by Acute Market Reports enables our clients to make timely, well-considered business decisions. We partner with a wide range of industry participants to provide cutting-edge strategic research solutions to our global clients.
